Debenture Agreements in the Biotechnology Industry
78 Contracts & Agreements
- Advaxis, Inc. (1 contract)
- ANAVEX LIFE SCIENCES CORP. (3)
- Anixa Biosciences Inc (1)
- AzurRx BioPharma, Inc. (2)
- BIOVIE INC. (1)
- BIOXYTRAN, INC (4)
- CareDx, Inc. (1)
- Cellectar Biosciences, Inc. (1)
- Chanticleer Holdings, Inc. (2)
- GENEREX BIOTECHNOLOGY CORP (6)
- GeoVax Labs, Inc. (1)
- GT Biopharma, Inc. (10)
- HARBOR DIVERSIFIED, INC. (2)
- IMMUNE PHARMACEUTICALS INC (5)
- Inspyr Therapeutics, Inc. (8)
- MATEON THERAPEUTICS INC (2)
- Organicell Regenerative Medicine, Inc. (1)
- Propanc Biopharma, Inc. (2)
- Protalix BioTherapeutics, Inc. (1)
- Q BioMed Inc. (8)
- Qrons Inc. (7)
- RITTER PHARMACEUTICALS INC (1)
- SELLAS Life Sciences Group, Inc. (2)
- TG THERAPEUTICS, INC. (1)
- Tonix Pharmaceuticals Holding Corp. (2)
- Trovagene, Inc. (1)
- VACCINEX, INC. (2)
- 8% Senior Convertible Debenture Due December 22, 2025 (RITTER PHARMACEUTICALS INC, Filed With SEC on December 22, 2022)
- Fourth Amendment to $15,000 8% Convertible Debenture, dated October 7, 2021 (Qrons Inc., Filed With SEC on December 1, 2021)
- Fifth Amendment to $10,000 8% Convertible Debenture, dated October 7, 2021 (Qrons Inc., Filed With SEC on December 1, 2021)
- The Convertible Debenture (Q BioMed Inc., Filed With SEC on October 7, 2021)
- Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on June 21, 2021)
- Form of Debenture (Q BioMed Inc., Filed With SEC on February 16, 2021)
- Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on January 12, 2021)
- Form of Debenture (Q BioMed Inc., Filed With SEC on December 29, 2020)
- Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on October 29, 2020)
- 7% Original Issue Discount Senior Convertible Debenture due August 3, 2021 (VACCINEX, INC., Filed With SEC on August 14, 2020)
- Form of 7% Original Issue Discount Senior Secured Convertible Debenture due August 3, 2021 (VACCINEX, INC., Filed With SEC on July 31, 2020)
- Form of 5% Original Issue Discount Senior Secured Convertible Debenture dated June 26, 2020 (GeoVax Labs, Inc., Filed With SEC on June 26, 2020)
- 8% Convertible Debenture of Bioxytran, Inc. to Power Up Lending Group LLC in the Principal Amount of $64,900 dated March 18, 2020 (BIOXYTRAN, INC, Filed With SEC on March 26, 2020)
- Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on March 6, 2020)
- 8% Convertible Debenture of Bioxytran, Inc. to Power Up Lending Group LLC in the Principal Amount of $56,600 dated January 18, 2020 (BIOXYTRAN, INC, Filed With SEC on February 26, 2020)
- Form of Debenture (Q BioMed Inc., Filed With SEC on December 12, 2019)
- Convertible Debenture of Bioxytran, Inc. to Peak One Opportunity Fund, L.P. in the Principal Amount of $120,000 dated October 22, 2019 (BIOXYTRAN, INC, Filed With SEC on November 5, 2019)
- 8% Convertible Debenture of Bioxytran, Inc. to Peak One Opportunity Fund, L.P. in the Principal Amount of $120,000 dated October 22, 2019 (BIOXYTRAN, INC, Filed With SEC on October 28, 2019)
- Form of Debenture (Q BioMed Inc., Filed With SEC on October 15, 2019)
- Form of 10% OID Convertible Delayed Draw Debenture (BIOVIE INC., Filed With SEC on September 25, 2019)
- The Convertible Debenture (Q BioMed Inc., Filed With SEC on September 6, 2019)
- Form of Debenture, issued by the Company to PeakOne (MATEON THERAPEUTICS INC, Filed With SEC on April 18, 2019)
- Form of Debenture, issued by the Company to the Bridge Investors (MATEON THERAPEUTICS INC, Filed With SEC on April 18, 2019)
- Amendment to 8% Secured Debentures by and between the Company and Debenture Holders (Chanticleer Holdings, Inc., Filed With SEC on April 1, 2019)
- First Amendment to $15,000 8% Convertible Debenture, dated September 9, 2018 (Qrons Inc., Filed With SEC on March 25, 2019)
- Second Amendment to the $10,000 8% Convertible Debenture, dated September 9, 2018 (Qrons Inc., Filed With SEC on March 25, 2019)
- Form of 2018 6% Convertible Debenture Issued by Biotech Products Services And Research, Inc., a Nevada corporation (Organicell Regenerative Medicine, Inc., Filed With SEC on November 1, 2018)
- Form of Debenture (IMMUNE PHARMACEUTICALS INC, Filed With SEC on October 10, 2018)
- Form of 10% Senior Convertible Debenture (GT Biopharma, Inc., Filed With SEC on September 28, 2018)
- Form of Debenture (Q BioMed Inc., Filed With SEC on September 24, 2018)
- Form of 10% Senior Convertible Debenture (GT Biopharma, Inc., Filed With SEC on September 7, 2018)
- Form of 10% Senior Convertible Debenture (GT Biopharma, Inc., Filed With SEC on August 3, 2018)
- Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on July 3, 2018)
- Form of Convertible Debenture (IMMUNE PHARMACEUTICALS INC, Filed With SEC on May 14, 2018)
- First Amendment to 8% Convertible Debenture, dated September 28, 2017, between the Company and CubeSquare LLC (Qrons Inc., Filed With SEC on March 2, 2018)
- 8% Convertible Debenture, dated September 27, 2017, between the Company and CubeSquare LLC (Qrons Inc., Filed With SEC on March 2, 2018)
- Modification to 12% Senior Secured Original Issue Discount Convertible Debenture, dated November 10, 2017 (AzurRx BioPharma, Inc., Filed With SEC on November 13, 2017)
- Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on September 12, 2017)
- Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on September 12, 2017)
- ORIGINALISSUE DISCOUNT CONVERTIBLE DEBENTURE (IMMUNE PHARMACEUTICALS INC, Filed With SEC on August 24, 2017)
